Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neckFlorence Duffaud, P. Fumoleau, Markus Borner et al.|European Journal of Cancer|2004Cited by 42
A European prospective observational study of enzalutamide (ENZA) in patients with metastatic castration-resistant prostate cancer (mCRPC): PREMISEHeather Payne, Marco De Santis, Roberto Bordonaro et al.|European Urology Open Science|2020Cited by 1
Pain outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving enzalutamide (ENZA) in a real-world setting: PREMISEDavid Mott, Marco Pavesi, Michael Herdman et al.|European Urology Open Science|2020Cited by 0